EUROPE AND NORTH AMERICA ACCOUNT FOR THE 60% OF PAH DRUGS MARKET SHARE

Ongoing developments in pipeline Pulmonary Arterial Hypertension (PAH) drugs combined with the growing awareness of the disease, particularly in developed countries has resulted in the growth of PAH market. Also, the market for PAH is growing moderately due to newer launches of pipeline drugs that target different pathways to suppress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in boosting the number of patients undergoing treatment.

According to the research report, “Global Pulmonary Arterial Hypertension (PAH) Market: Opportunities and Forecasts (2016-2021)”, global market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. The moderate rise in the market would be on account of low awareness about the disease coupled with the high treatment cost. Moreover, the global market is concentrated majorly in the developed regions while a major chunk of the market lies in the hands of a few key players.

Amongst the regions, Europe and North America together constituted more than 60% of the market share in the year 2015. Higher prevalence of heredity disorders such as Connective Tissue Disease, high per capita expenditure on healthcare and the availability of advanced infrastructure are the key factors backing the massive market share of these regions. In the forecast period, Asia Pacific region is anticipated to witness strong growth driven by rapidly developing countries such as India and China. Since the cost of treatment of this disease is extremely high, it makes it difficult for major population to afford the treatment. Further, lack of financial support from the government and unfavourable reimbursement policies have been restraining the growth in the market. However, growing incidences and awareness of this disease is anticipated to bring positive modifications in the compensation scenario in the coming years. Major global players from Europe and USA such as Actelion Pharmaceuticals, Gilead Sciences have been keeping a strong foothold of the market, with continuous R&D focusing on the development of newer drugs to target group 3 and 4 PAH, through prostacyclin. While some companies are developing breakthrough drugs such as Trevyent, Letairis etc., others have been targeting the symptoms of prostacyclin pathway.
For More Information follow the below link :
https://www.reportmarkets.com/199365-Global-Pulmonary-Arterial-Hypertension--PAH--Market--By-Drug-Class--By-Region--By-Country---Opportunities-and-Forecasts--2016-2021-----By-Drug-Class--Endothelin-Receptor-Antagonists--Prostacyclin---Pr

ReportMarkets is a leading platform of research reports, journals, country and company research, daily news and deals landscapes. To support decision makers, planning, financial and marketing teams across the world, we source thousands of reports from trusted and preferred publishers on key industries. Our powerful ‘market research tool’ with sophisticated refined search capabilities ensures all potential business opportunities, market insights, outlook and happenings across your industry reach you at the right time.

Phone : +1 928 592 4068
Email : sales@reportmarkets.com
3221 Tranquility
Ln Herndon
VA 20171, USA.

This release was published on openPR.